Zhejiang Jingxin Pharmaceutical002020.SZValuation Analysis

As of Oct 19, 2026, Zhejiang Jingxin Pharmaceutical (002020.SZ) trades at a P/E of 13.50x, P/B of 1.62x, P/S of 2.44x, and a dividend yield of 2.96%.
Longitudinal percentile comparison: P/E sits at the 19th percentile over the trailing 10Y window (vs. 9th percentile over 3Y); P/B sits at the 5th percentile over the trailing 10Y window (vs. 7th percentile over 3Y); P/S sits at the 34th percentile over the trailing 10Y window (vs. 23rd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 6th percentile within its industry and the 11th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 9.23%, ranking at the 100th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 13.7 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 9.23% total shareholder yield, 2.96% is paid out as dividends and roughly 6.27% is implied to come from buybacks — both channels are meaningfully in play. Zhejiang Jingxin Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.